Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
Abstract Background Physical activity is known to have anti-cancer effects, including immunomodulatory actions. This study investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 therapy to enhance efficacy in patients with unresectable HCC. Methods The...
Main Authors: | Xue-Feng Liu, Xiao-Dong Zhu, Long-Hai Feng, Xiao-Long Li, Bin Xu, Kang-Shuai Li, Nan Xiao, Ming Lei, Hui-Chuan Sun, Zhao-You Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40164-022-00275-0 |
Similar Items
-
Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
by: Jia M, et al.
Published: (2022-09-01) -
Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01) -
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
by: Peng Guo, et al.
Published: (2022-10-01) -
The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
by: Zongren Ding, et al.
Published: (2024-06-01) -
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021-03-01)